Skip to main content
Log in

Competition mounts but ‘Viagra’ stays on top

  • Newsletter Article
  • Published:
Inpharma Weekly

Abstract

The list of therapeutic options for male erectile dysfunction continues to expand. Notably, 2 new oral therapies have entered clinical trials. However, preliminary results suggest that neither phentolamine nor apomorphine pose an immediate threat to sildenafil’s pre-eminent position as first-line therapy. Nevertheless, emergence of new agents will provide more options, especially for men who do not respond to sildenafil or for whom the agent is contraindicated. However, continued evaluation of intraurethral alprostadil has yielded disappointing results, as reported at the American Urological Association (AUA) meeting [ San Diego, US; June 1998 ].

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bankhead, C. Competition mounts but ‘Viagra’ stays on top. Inpharma Wkly. 1149, 11–12 (1998). https://doi.org/10.2165/00128413-199811490-00024

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128413-199811490-00024

Keywords

Navigation